Skip to content

Schrodinger SDGR Equity method investments (Note 11)

Equity method investments (Note 11) at other companies

Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
Charles River Laboratories logo
Charles River LaboratoriesCRL
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$58.6M-1.6%
Gross profit$29.5M-5.1%
Operating income-$48.8M+4.1%
Net income-$60.0M-0.4%
EPS (diluted)-$0.81+1.2%

Balance sheet

See full
Cash & equivalents$267.7M-20.7%
Total debt$107.0M-7.9%
Total equity$313.5M-16.1%
Total assets$634.2M-14.6%

Cash flow

See full
Operating cash flow-$14.8M-110%
CapEx$2.5M+321%
Free cash flow-$17.3M-112%

Valuation

See full
Market cap$1.15B-19.7%
Enterprise value$984.71M-18.3%
P/S4.5×-1.7×

Profitability

See full
Gross margin55.3%-7.3pp
Operating margin-64.7%-12.0pp
Net margin-68.5%
FCF margin9.6%+5.1pp

Returns & leverage

See full
Return on equity-45.7%
Debt / equity0.3×0.0×
Current ratio2.7×-0.7×

Where this comes from

Reported directly by Schrodinger in its filing.

Tagged under the XBRL concept us-gaap:EquityMethodInvestments.

The official record: Schrodinger’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schrodinger's equity method investments (note 11).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schrodinger's equity method investments (note 11)?
Schrodinger (SDGR) reported equity method investments (note 11) of $39.83M in Q1 2026.
How has Schrodinger's equity method investments (note 11) changed year-over-year?
Schrodinger's equity method investments (note 11) increased by 32.3% year-over-year, from $30.11M to $39.83M.
What is the long-term trend for Schrodinger's equity method investments (note 11)?
Over 5 years (2020 to 2025), Schrodinger's equity method investments (note 11) has grown at a 10.0% compound annual growth rate (CAGR), from $45.66M to $73.65M.